This knowledge gap has become increasingly pressing with the widespread adoption of exome and genome sequencing in clinical and research settings, coupled with recommendations to report incidental RET findings, highlighting the urgent need to better understand medullary thyroid cancer risk in incidental cases. Here, RET is linked to medullary thyroid gland carcinoma.